非清髓性异基因造血干细胞移植的基础实验及临床研究  

Basic and clinical studies of non-myeloablative allogeneic hematopoietic stem cell transplantation

作　　者：金楠[1] 陈宝安[1] 

机构地区：[1]江苏省南京市东南大学附属中大医院血液科,江苏省南京市210009

出　　处：《中国组织工程研究与临床康复》2009年第10期1955-1958,共4页Journal of Clinical Rehabilitative Tissue Engineering Research

摘　　要：非清髓性异基因造血干细胞移植现在被广泛应用在由于年龄或合并症而不适应行传统造血干细胞移植的患者身上,采用非清髓性预处理策略,移植后形成供受体造血细胞混合嵌合状态,淋巴细胞供受体双向免疫耐受,即非清髓性干细胞移植。通过非清髓性预处理方案,移植后形成供受体细胞嵌合状态,发挥移植物抗肿瘤效应,来达到治疗目的,与传统造血干细胞移植相比有较低的移植相关死亡率,术后移植物抗宿主疾病发生减少,且扩大了适应证范围,并且非清髓性预处理方案的改进、移植后相关疾病发生的防治可以进一步提高治疗效果。目前虽然有许多治疗策略被提出,并在动物模型上取得了成功,但其在人体方面的应用仍需得到进一步的证实和研究。Non-myeloablative allogeneic hematopoietic stem cell transplantation has been extensively applied in patients with hematologic malignancies who are ineligible for conventional hematopoietic stem cell transplantation because of age or medical comorbidities. Non-myeloablative regimens lead to an initial state of mixed hematopoietic chimerism which can produce a marked effect of graft versus tumor to treat the diseases. Compared with the conventional hematopoietic stem cell transplantation, non-myeloablative allogeneic hematopoietic stem cell transplantation has a lower transplant-related mortality and incidence rate of graft-versus-host disease. The improvement of non-myeloablative regimens and the prophylaxis of diseases associated with transplantation can improve the therapeutic efficacy. Though many therapies have been introduced and proved to be successful in animal models, we still need to investigate the research trend and the problem on human body.

关 键 词：造血干细胞移植 异基因 非清髓性 

分 类 号：R394.2[医药卫生—医学遗传学]